Illumina’s Billion Cell Atlas expands as AI‑native drug developer Formation Bio becomes the latest member of the alliance, a move that could reshape AI‑driven drug discovery by giving researchers unprecedented single‑cell perturbation data to accelerate therapeutic development.
Illumina adds a third AI partner
San Diego‑based Illumina (NASDAQ: ILMN) announced on July 16, 2026 that Formation Bio joins the Billion Cell Atlas coalition, which already includes AstraZeneca, Merck, Eli Lilly and a handful of AI‑focused biotech firms. The alliance leverages Illumina’s genome‑wide perturbation platform, which has already generated more than 350 million sequenced cells and six petabytes of data. By pooling this massive dataset, members can train next‑generation AI models that predict how genetic changes affect cell behavior, a capability that has been out of reach for most enterprise AI teams.
Why the Atlas matters
The core of the Atlas is a library of single‑cell CRISPR perturbations across hundreds of disease‑relevant cell types. Unlike observational single‑cell atlases, Illumina’s dataset captures causal relationships—what happens when a gene is knocked out, over‑expressed, or edited. This “intervention‑level” information feeds directly into machine‑learning infrastructure, enabling large language models (LLMs) and generative AI frameworks to simulate disease pathways and forecast drug responses with higher fidelity.
Formation Bio’s use case
Formation Bio, founded by former Illumina executives, positions itself as an AI‑first biotech that acquires late‑stage assets and accelerates them through data‑driven development. “We are excited to leverage the Illumina Billion Cell Atlas to credential therapeutic‑area hypotheses and target‑indication pairs against a new layer of cell‑specific causal biology,” said CEO Benjamine Liu. For the company, the Atlas promises three concrete advantages:
- De‑risking asset selection – By cross‑referencing perturbation signatures with genetic and clinical evidence, Formation can prioritize programs with the strongest mechanistic rationale.
- Refining patient stratification – Single‑cell resolution helps identify subpopulations that are most likely to respond, informing trial design and reducing enrollment costs.
- Speeding preclinical cycles – AI agents can simulate thousands of virtual experiments, cutting down the need for costly wet‑lab validation.
Industry context
Illumina’s move arrives as enterprise AI platforms scramble to embed biology into their core offerings. Google’s DeepMind has made headlines with AlphaFold, but its focus remains on protein structure prediction rather than functional genomics. Amazon’s AWS HealthLake provides a managed data lake for health records, yet it lacks the perturbation depth needed for causal inference. Microsoft’s Azure for Genomics offers scalable compute but still depends on third‑party datasets. The Billion Cell Atlas thus differentiates itself by delivering a proprietary, intervention‑rich dataset that can be directly consumed by AI cloud platforms, AI chips, and automation pipelines.
Competitive advantage
From a technical standpoint, the Atlas aligns with the emerging “foundation model” paradigm that Gartner predicts will dominate AI research by 2027, with a projected $190 billion market for AI‑enabled drug discovery tools. Illumina’s data volume—six petabytes and counting—provides the scale required to train foundation models that outperform niche, manually curated datasets. Moreover, the alliance’s open‑access policy for member APIs means that AI developers can integrate the data into existing machine‑learning infrastructure, whether they run on NVIDIA H100 GPUs, custom AI chips, or cloud‑native services from Google Cloud or AWS.
Implications for enterprise marketing
While the Atlas is a scientific engine, its downstream effects ripple into commercial functions. Pharma marketers can harness the same AI models to generate evidence‑based messaging, tailor outreach to specific patient cohorts, and predict market uptake based on mechanistic efficacy. In a landscape where Salesforce and Adobe are extending AI capabilities into life‑science CRM and experience platforms, the Atlas offers a data source that can feed predictive analytics, enabling more precise, data‑driven campaign planning. Enterprise marketing teams can leverage these insights to craft evidence‑based, patient‑centric campaigns, aligning with AI‑enhanced CRM tools from Salesforce and Adobe.
Expert perspective
Kyle Farh, Illumina’s vice president of Artificial Intelligence, emphasized the shift from observational to interventional data: “The next frontier of AI in biology hinges on the creation of foundational training datasets. Up until now, most single‑cell data has been observational. We aim to change that, and in the process, reimagine what is possible in biology.”
Looking ahead
The alliance’s roadmap includes expanding the cell‑type repertoire to cover rare disease models and integrating multi‑omics layers such as proteomics and epigenomics. If successful, the combined dataset could become the de‑facto standard for training AI agents that design, test, and optimize therapeutics end‑to‑end—potentially compressing a decade‑long R&D timeline into a few years.
Market Landscape
The AI‑driven drug discovery market is rapidly consolidating. IDC estimates that AI‑enabled biotech startups raised $12 billion in 2025, a 45 % increase from the previous year. At the same time, Forrester projects that enterprises adopting AI‑powered R&D platforms will see a 30 % reduction in time‑to‑market for new indications. Illumina’s Billion Cell Atlas positions the company at the intersection of two trends: the explosion of single‑cell genomics data and the scaling of foundation models for biology. Competitors such as Recursion Pharmaceuticals and Insilico Medicine have built proprietary perturbation libraries, but none match Illumina’s combination of data volume, breadth of cell types, and partnership network.
Top Insights
- The Billion Cell Atlas offers the first large‑scale, intervention‑level single‑cell dataset, enabling AI models to predict causal gene‑cell relationships rather than mere correlations.
- Formation Bio’s entry illustrates how AI‑native biotechs can use the Atlas to de‑risk asset selection, refine patient stratification, and shorten preclinical cycles.
- Compared with Google’s AlphaFold and Amazon’s HealthLake, Illumina provides a unique blend of genomic perturbation depth and open‑access APIs for enterprise AI platforms.
- Enterprise marketing teams can leverage Atlas‑derived insights to craft evidence‑based, patient‑centric campaigns, aligning with AI‑enhanced CRM tools from Salesforce and Adobe.
- Gartner forecasts a $190 billion market for AI‑enabled drug discovery by 2027, and Illumina’s data scale positions it to become a cornerstone of that ecosystem.
Power Tomorrow’s Intelligence — Build It with TechEdgeAI
